Richard L Raymond

Array ( [id] => 18368161 [patent_doc_number] => 11648309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Anti-netrin-1 antibody [patent_app_type] => utility [patent_app_number] => 16/657200 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 11891 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274487 [patent_doc_number] => 20210380685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => Methods of Treating Rheumatoid Arthritis [patent_app_type] => utility [patent_app_number] => 17/283690 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18326723 [patent_doc_number] => 20230124851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => B7H3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/283902 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15616107 [patent_doc_number] => 20200078458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => Cancer-Cell-Specific Antibody, Anticancer Drug, and Cancer Testing Method [patent_app_type] => utility [patent_app_number] => 16/578861 [patent_app_country] => US [patent_app_date] => 2019-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16578861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15678513 [patent_doc_number] => 20200093920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1 [patent_app_type] => utility [patent_app_number] => 16/573374 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64645 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589741 [patent_doc_number] => 20200071405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 [patent_app_type] => utility [patent_app_number] => 16/570129 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17157267 [patent_doc_number] => 20210318318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => Kinase Activity In Tumors [patent_app_type] => utility [patent_app_number] => 17/271712 [patent_app_country] => US [patent_app_date] => 2019-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168838 [patent_doc_number] => 20210322508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => PEPTIDES AND COMPOSITIONS FOR TARGETED TREATMENT AND IMAGING [patent_app_type] => utility [patent_app_number] => 17/268046 [patent_app_country] => US [patent_app_date] => 2019-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 158609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17268046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363671 [patent_doc_number] => 20200017600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => VARIANTS OF CD38 ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/512206 [patent_app_country] => US [patent_app_date] => 2019-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16512206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067331 [patent_doc_number] => 20210269546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38 [patent_app_type] => utility [patent_app_number] => 17/259491 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067306 [patent_doc_number] => 20210269521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => BISPECIFIC ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/254862 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854964 [patent_doc_number] => 20210155709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => ANTIBODIES ANTI TUMOR ASSOCIATED ANTIGENS AND METHOD FOR OBTAINING THEM [patent_app_type] => utility [patent_app_number] => 17/252864 [patent_app_country] => US [patent_app_date] => 2019-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17252864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17141739 [patent_doc_number] => 20210309751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => REVERSED UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS FOR TARGETING OF DIVERSE MULTIPLE ANTIGENS AND METHOD OF MANUFACTURING THE SAME AND USE OF THE SAME FOR TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/251447 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15901209 [patent_doc_number] => 20200150123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => TUMOR MARKERS FUS, SMAD4, DERL1, YBX1, PS6, PDSS2, CUL2, AND HSPA9 FOR ANALYZING PROSTATE TUMOR SAMPLES [patent_app_type] => utility [patent_app_number] => 16/432199 [patent_app_country] => US [patent_app_date] => 2019-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16432199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14996279 [patent_doc_number] => 20190317097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => Novel Biomarkers for Sub-Typing Pancreatic Ductal Adenocarcinoma [patent_app_type] => utility [patent_app_number] => 16/422778 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16792998 [patent_doc_number] => 20210122815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => ANTI-INTERLEUKIN-17A ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/055252 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858567 [patent_doc_number] => 11439705 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Anti-TIGIT antibodies [patent_app_type] => utility [patent_app_number] => 16/413557 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 81 [patent_no_of_words] => 39613 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067315 [patent_doc_number] => 20210269530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => CONDITIONALLY ACTIVATED BINDING PROTEIN COMPRISING A STERICALLY OCCLUDED TARGET BINDING DOMAIN [patent_app_type] => utility [patent_app_number] => 17/055103 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11332 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007129 [patent_doc_number] => 20210238290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => PROTEINS BINDING NKG2D, CD16 AND P-CADHERIN [patent_app_type] => utility [patent_app_number] => 17/053558 [patent_app_country] => US [patent_app_date] => 2019-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22328 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243519 [patent_doc_number] => 20210363262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => ANTIBODY SPECIFICALLY BINDING TO C-MET, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/052196 [patent_app_country] => US [patent_app_date] => 2019-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052196 [rel_patent_id] =>[rel_patent_doc_number] =>)